Prevest Denpro Ltd Q2 FY2026 Concall Summary

Key Takeaways

• Export-led quarter, domestic recovers: Export revenue grew 24% YoY as crisis-hit countries stabilized, while domestic sales rebounded 18.97% QoQ after a disruption-heavy Q1.
• Digital dentistry is the declared growth engine: In-house 3D printer assembly has begun, resin capacity is built at 3,000 kg/month (under 5% utilized), and management expects the vertical to become a major pillar.
• Margins are defended, not expanded: Gross margins held at ~35% through a deliberate focus on value-added, low-competition products; management sees no need to expand them and did not commit to a higher band.
• The US subsidiary is working through tariffs: Axiodent grew ~45% in H1 via private-label and own-brand sales; management calls tariffs temporary and has managed them through pricing realignment and buyer absorption.
• What to watch next quarter: Whether H2 crosses the promised 20% growth, the pace of new biomaterials commercialization, and any sign that 3D printer and disinfectant volumes are converting capacity into revenue.

Export Recovery & Geographic Mix

• Crisis-hit markets stabilized: Countries that faced currency volatility and financial crises last year have resolved those issues, leading to increased demand and regular orders; management expects this momentum to continue and improve in H2.
• US market grew ~45% in H1: Driven by private-label arrangements and own-brand Axiodent sales; the subsidiary has begun contributing meaningfully and secured initial orders that open long-term opportunities.
• Tariff management, not tariff panic: Recently introduced US tariffs have been addressed through pricing realignment and buyer absorption; management considers them a temporary phase and expects similar growth rates in the coming year.
• New geographies in pipeline: The company is actively engaging distributors in new geographies, with several discussions at an advanced stage.

Modi: "Several key countries are now showing clearer signs of stabilization which has directly contributed to this positive export momentum."

Domestic Business: Disrupted Then Recovered

• Q1 hit by three external shocks: A near war-like situation in Jammu disrupted operations for ~10 days, heavy rains and river flooding added another 10–15 days of downtime, and a GST revision from 12% to 5% triggered 15–20 days of distributor realignment on pricing and stock.
• Q2 snapped back: Domestic revenue grew 18.97% QoQ and 12.88% YoY, confirming the disruptions were temporary; H2 domestic growth is expected in double digits.
• Field presence being strengthened: The networking team is being expanded to increase field presence, improve customer connect, and ensure better clinic support; early signs are positive though the work is still in progress.

Munjal: "Local disruptions from the near war-like situations in Jammu to unusually heavy rains and river flooding created operational hurdles. The GST revisions also led to temporary realignment with our distributor network. Even with all these challenges, our domestic operations remained steady."

Digital Dentistry Build-Out

• 3D printer assembly in-house: The company has started in-house assembly of 3D printers for dental applications, focusing on chairside printing solutions for clinics.
• Resin capacity far ahead of demand: Capacity for 3,000 kg of resin per month has been built, but utilization is under 5%; the resin is bundled with printers to ensure compatibility, and dentists prefer buying directly from the company for this reason.
• Scanner development underway: The company is moving deeper into advanced digital solutions with development of both 3D printers and scanners, combining internal R&D with global technology partners.
• Medium-term pillar: Management expects the digital dentistry vertical to become one of the important pillars of the business, with early market feedback described as very encouraging.

Modi: "We have built the capacity for producing 3000 kilograms of the resin every month, but it is just the beginning. So, we are not even utilizing 5% of our capacity."

Product Portfolio Expansion

• Rotoflex endodontic files launched: The newest launch is showing strong acceptance among dental practitioners; repeat demand reassures that the product is hitting clinical requirements.
• Disinfectant range commercialized: Marks the beginning of a new vertical aligned with rising demand for hygiene-driven products in dental and medical settings; will be scaled thoughtfully over coming quarters with meaningful potential seen both domestically and in selected export markets.
• Biomaterials contributing, more coming: Biomaterials developed by R&D have been successfully introduced and are contributing significantly to revenue; new biomaterials including bone grafting materials are under development for commercialization very soon.
• Oradox oral care gaining traction: The brand is slowly gaining visibility and customer acceptance; more hiring in senior and frontline roles has been initiated to drive sales, though scaling meaningfully will take time.
• No commercialization timeline for pipeline products: R&D is actively working on new innovative products, but management stated commercialization timelines cannot be given until products are ready.

Margin Structure & Cost Discipline

• Margins sustained at ~35%: The company focuses only on value-added, high-margin products with less competition; operational expenses have not grown substantially despite new product lines, so profitability is sustained.
• No margin expansion commitment: When asked directly about margin expansion, management stated they do not need expansion, are focused on existing lines, and are careful about maintaining margins; no proportion or breakdown of new product margins was provided.
• Productivity gains expected in H2: Further gains are anticipated from ongoing optimization of manufacturing processes; capacity utilization across key product lines has already improved.
• Bottom-line to outgrow top-line: Management expects profitability to increase more than revenue because all necessary investments have been made and further expense expansion is within budgeted thresholds.

Modi: "We produce products which are only value-added products where the margins are good. So, we are able to sustain and maintain our margins."

Guidance & Commitments

Key Metrics